{"url_path":"/sec/whwk/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1422142/0001193125-26-220656-index.html","accession_number":"0001193125-26-220656","cik":"0001422142","ticker":"WHWK","issuer_name":"Whitehawk Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1422142/0001193125-26-220656-index.html","primary_entity_key":"0001422142","primary_entity_name":"Whitehawk Therapeutics, Inc."},"word_count":117,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNumber\n  \nDescription\n\n 4.1\n  \n[Form of Pre-Funded Warrant to Purchase Common Stock.](d854431dex41.htm)\n\n10.1\n  \n[Securities Purchase Agreement, dated May 12, 2026 and each purchaser identified on Exhibit A thereto.](d854431dex101.htm)\n\n10.2\n  \n[Form of Registration Rights Agreement, by and among Whitehawk Therapeutics, Inc. and the purchasers thereto.](d854431dex102.htm)\n\n99.1\n  \n[Press Release, dated May 13, 2026.](d854431dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDated: May 13, 2026\n \n\n \n\n \nWHITEHAWK THERAPEUTICS, INC.\n\n \n\n \n \n \n\n/s/ Scott Giacobello\n\n \n\n \n\n \nScott Giacobello\n\n \n\n \n\n \nChief Financial Officer"}